Medi-Caps Q4 FY26 Results: PAT Rs 3.04 Cr
- May 22, 2026
- Posted by: Kashish Aggarwal
- Category: News
Medi-Caps Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 3.04 crore for the quarter ended March 31, 2026, up 76.7% YoY compared to Rs 1.72 crore in Q4 FY25. Revenue from operations stood at Rs 3.45 crore. Results are on a Consolidated basis. Medi-Caps is a Pharmaceutical Capsules company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Medi-Caps Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | 3.45 | N/A | N/A |
| Net Profit | 3.04 | 1.72 | +76.7% |
| Basis | Consolidated | ||
Note: Medi-Caps Q4 FY26 results declared May 21, 2026. Verify from BSE/NSE audited filings before investment decisions.
Medi-Caps Q4 FY26 Performance Analysis
The Medi-Caps Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. Strong PAT growth of 76.7% YoY to Rs 3.04 crore demonstrates significant earnings improvement. Medi-Caps operates in the Pharmaceutical Capsules sector, which benefited from India’s GDP growth above 6.5% in FY26.
Revenue of Rs 3.45 crore reflects steady business conditions in the Pharmaceutical Capsules sector.
Screen the best stocks on the Univest Screener.
Key Factors Driving Medi-Caps Q4 FY26 Results
Revenue and Business Performance
The revenue of Rs 3.45 crore was for the quarter ended March 31, 2026. Revenue momentum reflects steady demand in the Pharmaceutical Capsules business.
Profitability and Margins
The business PAT of Rs 3.04 crore is up 76.7% YoY. The strong PAT growth demonstrates improving operational leverage and cost discipline.
India Macro Backdrop
The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore for FY27, and resilient domestic consumption. RBI’s accommodative stance supported credit and demand conditions. The Pharmaceutical Capsules sector saw strong tailwinds during this period.
FY27 Outlook
Following the firm results, management commentary on FY27 revenue guidance, margin expansion roadmap, and capital allocation will be key investor watchpoints. The Pharmaceutical Capsules sector continues to benefit from India’s long-term structural growth.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the company
What is Medi-Caps Q4 FY26 net profit?
Ans. Medi-Caps Q4 FY26 PAT of Rs 3.04 crore, up 76.7% YoY from Rs 1.72 crore in Q4 FY25. Results declared May 21, 2026, on a Consolidated basis.
What is Medi-Caps Q4 FY26 revenue?
Ans. Medi-Caps Q4 FY26 revenue from operations was Rs 3.45 crore. Verify from BSE/NSE filings.
When were Medi-Caps Q4 FY26 results declared?
Ans. Medi-Caps Q4 FY26 results were declared on May 21, 2026, at the board of directors meeting approving audited Q4 and FY26 financial statements.
Is Medi-Caps a good investment after Q4 FY26?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk. This article is for educational purposes only. Consult a SEBI-registered financial advisor before investing.
Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.
